NASDAQ · Biotechnology
OCGN (OCGN) Stock
$1.25
+1.63%
NASDAQ: OCGN
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Ocugen Signs Term Sheet to License Retinitis Pigmentosa Gene Therapy to Roots Pharmaceutical, Al-Dhow in MENA Region
MT Newswires · Jul 13, 2026
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
GlobeNewswire · Jul 13, 2026
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances
MarketBeat · Jul 11, 2026
Ocugen to Participate in Upcoming July Industry Conferences
GlobeNewswire · Jul 1, 2026
Ocugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst View
Simply Wall St. · Jun 25, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held1.68%
Institutions Held34.57%
Institutions Float Held35.16%
Peer Comparison
About OCGN
OCGN is led by CEO Shankar Musunuri, publicly traded since 2014.
OCGN stock trades at $1.25 with a market capitalization of $423.15M. The stock is valued at a price-to-earnings (P/E) ratio of -6.48, price-to-book of 83.35, price-to-sales of 114.48. Over the past 52 weeks the stock has ranged between $0.90 and $2.73, and currently trades 54.1% below its 52-week high.
On profitability, OCGN generates a return on equity (ROE) of 566.67% — well above the market average, a sign of a high-quality business, return on capital employed of -183.04%, an operating margin of -1575.00%, a net profit margin of -16.05%.